Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
Completed · Phase 1
Conditions studied: Moderate Hepatic Impairment, Healthy
In brief
This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of KBP-5074.
Key facts
- Study ID
- NCT04534699
- Run by
- KBP Biosciences
- People needed
- 12
- Starts
- 2020-08-27
- Expected to finish
- 2020-11-19
- Last updated by the study team
- 2025-12-16
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orlando Clinical Research Center (OCRC) — Orlando, Florida, United States
- Texas Liver Institute (TLI) — San Antonio, Texas, United States
- Clinical Trials of Texas (CTT) — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.